Papers - Yamazaki, Rie

Simultaneous quantification of dasatinib, nilotinib, bosutinib, and ponatinib using high-performance liquid chromatography–Photodiode array detection

Yokoyama Y., Nozawa E., Morita M., Ishikawa E., Mori T., Sakurai M., Kikuchi T., Matsuki E., Yamazaki R., Kataoka K., Jibiki A., Kawazoe H., Suzuki S., Nakamura T.

Journal of Clinical Laboratory Analysis (Journal of Clinical Laboratory Analysis)  36 ( 8 )  2022.08

ISSN  08878013

　View Summary

Background: Dasatinib, nilotinib, and bosutinib, second-generation tyrosine kinase inhibitors (TKIs), and ponatinib, a third-generation TKI, are approved pharmaceuticals used in the treatment of chronic myeloid leukemia (CML). Although liquid chromatography-tandem mass spectrometry assays for simultaneous quantification of the four TKIs in human serum have been reported in the literature, a high-performance liquid chromatography (HPLC) assay that simultaneously quantifies these compounds has not yet been developed. This study aims to establish and validate an efficient HPLC analytical method using a photodiode array (PDA) detector for the simultaneous quantification of the four TKIs. Methods: Calibration standards were prepared by serial dilution of serum samples containing the four TKIs, followed by solid-phase extraction. The four TKIs were eluted in order within 10 min using a binary HPLC gradient system. Results: The calibration ranges were 2–500 ng/ml for dasatinib, 100–5000 ng/ml for nilotinib, and 10–500 ng/ml for bosutinib and ponatinib. Intra-day and inter-day precision and accuracy values were found to be in accordance with the U.S. Food and Drug Administration guidelines. The recovery rates were 92.9%–96.0%, 80.7%–86.1%, 91.6%–99.0%, and 86.4%–92.6% for dasatinib, nilotinib, bosutinib, and ponatinib, respectively. Conclusion: To the best of our knowledge, this is the first report of an HPLC-PDA analytical method that allows efficient simultaneous quantification of the four TKIs in the serum of patients with CML. We believe that the method developed herein can improve the efficiency of therapeutic drug monitoring in patients with CML in clinical practice.

• Access to Document (DOI)

Comparison of cryoprotectants in hematopoietic cell infusion–related adverse events

Ikeda K., Minakawa K., Yamahara K., Yamada-Fujiwara M., Okuyama Y., Fujiwara S.i., Yamazaki R., Kanamori H., Iseki T., Nagamura-Inoue T., Kameda K., Nagai K., Fujii N., Ashida T., Hirose A., Takahashi T., Ohto H., Ueda K., Tanosaki R.

Transfusion (Transfusion)  62 ( 6 ) 1280 - 1288 2022.06

ISSN  00411132

　View Summary

Background: The standard cryoprotectant for human cellular products is dimethyl sulfoxide (DMSO), which is associated with hematopoietic cell infusion-related adverse events (HCI-AEs) in hematopoietic stem cell transplantation including peripheral blood stem cell (PBSC) transplantation (PBSCT). DMSO is often used with hydroxyethyl starch (HES), which reduces DMSO concentration while maintaining the postthaw cell recovery. The cryoprotectant medium CP-1 (Kyokuto Pharmaceutical Industrial) is widely used in Japan. After mixture of a product with CP-1, DMSO and HES concentrations are 5% and 6%, respectively. However, the safety profile of CP-1 in association with HCI-AEs has not been investigated. Study Design and Methods: To compare CP-1 with other cryoprotectants, we conducted a subgroup analysis of PBSCT recipients in a prospective surveillance study for HCI-AEs. Moreover, we validated the toxicity of CP-1 in 90 rats following various dose administration. Results: The PBSC products cryopreserved with CP-1 (CP-1 group) and those with other cryoprotectants, mainly 10% DMSO (non-CP-1 group), were infused into 418 and 58 recipients, respectively. The rate of ≥grade 2 HCI-AEs was higher in the CP-1 group, but that of overall or ≥grade 3 HCI-AEs was not significantly different, compared to the non-CP-1 group. Similarly, after propensity score matching, ≥grade 2 HCI-AEs were more frequent in the CP-1 group, but the ≥grade 3 HCI-AE rate did not differ significantly between the groups. No significant toxicity was detected regardless of the CP-1 dose in the 90 rats. Conclusions: Infusion of a CP-1-containing PBSC product is feasible with the respect of HCI-AEs.

• Access to Document (DOI)

Novel Indicators of Transplant Outcomes for PhALL: Current Molecular-Relapse-Free Survival

Nakasone H., Kako S., Tachibana T., Tanaka M., Onizuka M., Takahashi S., Yokota A., Fujiwara S.I., Sakura T., Sakaida E., Fujisawa S., Yamazaki R., Gotoh M., Hagihara M., Aotsuka N., Tsukada N., Hatta Y., Shimizu H., Usuki K., Watanabe R., Mori T., Yano S., Kanamori H., Kanda Y.

Transplantation and Cellular Therapy (Transplantation and Cellular Therapy)  27 ( 9 ) 800.e1 - 800.e8 2021.09

ISSN  26666367

　View Summary

Molecular relapse after allogeneic hematopoietic cell transplantation (allo-HCT) has been thought to predict clinical relapse in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia (PhALL). Tyrosine kinase inhibitor (TKI) administration after allo-HCT may dynamically change the status from molecular relapse to molecular remission, but these state changes cannot be accurately represented by conventional survival indicators such as relapse-free survival, where events are usually considered irreversible. We aimed to develop novel indicators of transplant outcomes for allo-HCT recipients with PhALL and to visualize current molecular-relapse-free survival (CMRFS) and current on-TKI status (CTKI), treating molecular relapse or TKI administration after allo-HCT as a reversible event. We retrospectively analyzed 286 patients with PhALL who received allo-HCT between 2000 and 2016 in order to develop the indicators. CMRFS was defined as the probability of molecular remission without clinical relapse or death at any time after allo-HCT. Similarly, CTKI was defined as the probability of TKI administration without clinical relapse or death at any time after allo-HCT. The 1- and 5-year CMRFS rates were 67% and 59%, respectively, whereas the 1- and 5-year conventional molecular relapse-free survival rates were 42% and 37%. The 1- and 5-year CTKI rates were 14% and 8%, respectively. In a post hoc analysis focusing on patients who had achieved a molecular complete remission within 6 weeks (n = 201), the 5-year CMRFS rate (71%) was similar to the 5-year conventional molecular relapse-free survival (molRFS) rate (70%) in the non-TKI group. On the other hand, the 5-year CMRFS rate in the TKI group was 61%, whereas the 5-year conventional molRFS rate was only 38%. CMRFS and CTKI might become useful indicators of transplant success in terms of survival, leukemia-free status, and treatment-free status at any time point. Future extension of these survival models to other clinical situations is warranted.

• Access to Document (DOI)

Clinical results of a massive blood transfusion protocol for postpartum hemorrhage in a university hospital in japan: A retrospective study

Ochiai D., Abe Y., Yamazaki R., Uemura T., Toriumi A., Matsuhashi H., Tanaka Y., Ikenoue S., Kasuga Y., Tanosaki R., Tanaka M.

Medicina (Lithuania) (Medicina (Lithuania))  57 ( 9 )  2021.09

ISSN  1010660X

　View Summary

Background and objectives: Massive postpartum hemorrhage (PPH) is the most common cause of maternal death worldwide. A massive transfusion protocol (MTP) may be used to provide significant benefits in the management of PPH; however, only a limited number of hospitals use MTP protocol to manage massive obstetric hemorrhages, especially in Japan. This study aimed to assess the clinical outcomes in patients in whom MTP was activated in our hospital. Materials and Methods: We retrospectively reviewed the etiology of PPH, transfusion outcomes, and laboratory findings among the patients treated with MTP after delivery in our hospital. Results: MTP was applied in 24 cases (0.7% of deliveries). Among them, MTP was activated within 2 h of delivery in 15 patients (62.5%). The median estimated blood loss was 5017 mL. Additional procedures to control bleeding were performed in 19 cases, including transarterial embolization (18 cases, 75%) and hysterectomy (1 case, 4.2%). The mean number of units of red blood cells, fresh frozen plasma, and platelets were 17.9, 20.2, and 20.4 units, respectively. The correlation coefficients of any two items among red blood cells, fresh frozen plasma, platelets, blood loss, and obstetrical disseminated intravascular coagulation score ranged from 0.757 to 0.892, indicating high levels of correlation coefficients. Although prothrombin time and activated partial thromboplastin time levels were significantly higher in the <150 mg/dL fibrinogen group than in the ≥150 mg/dL fibrinogen group at the onset of PPH, the amount of blood loss and blood transfusion were comparable between the two groups. Conclusions: Our MTP provides early access to blood products for patients experiencing severe PPH and could contribute to improving maternal outcomes after resuscitation in our hospital. Our study suggests the implementation of a hospital-specific MTP protocol to improve the supply and utilization of blood products to physicians managing major obstetric hemorrhage.

• Access to Document (DOI)

Toxoplasmosis after allogeneic hematopoietic stem cell transplantation: Impact of serostatus-based management

Amikura T., Kikuchi T., Kato J., Koda Y., Sakurai M., Yamazaki R., Mikita K., Saburi M., Nakazato T., Mori T.

Transplant Infectious Disease (Transplant Infectious Disease)  23 ( 3 )  2021.06

ISSN  13982273

　View Summary

Toxoplasmosis caused by Toxoplasma gondii (T. gondii) is a serious infectious complication after allogeneic hematopoietic stem cell transplantation (HSCT). The incidence of toxoplasmosis varies widely because of the variabilities of seroprevalence among patient populations. The incidence and the optimal management of toxoplasmosis after allogeneic HSCT in a patient population with a low seroprevalence have not been fully evaluated. We conducted a single-center retrospective study evaluating toxoplasmosis in Japanese patients who underwent allogeneic HSCT. Of the 728 evaluable patients, only 5 developed toxoplasmosis with a median onset of day 60 post-transplant (range, day 55-393). The cumulative incidence was 0.7% (95% CI: 0.3%-1.5%) at day 500 post-transplant. Four of the five patients succumbed due to toxoplasmosis. The more recently treated 220 patients (not the earlier 508 patients) were screened for the T. gondii serostatus, and prophylactic treatment with trimethoprim/sulfamethoxazole was applied. All five patients with toxoplasmosis were in the unscreened group, and there was no case of toxoplasmosis after the introduction of the screening and prophylactic treatment. Our results suggest that toxoplasmosis after allogeneic HST is rare but can develop as a life-threatening complication even in the populations with low seroprevalence, and that prophylactic treatment for seropositive patients could effectively prevent toxoplasmosis.

• Access to Document (DOI)

Cytomegalovirus retinitis after allogeneic hematopoietic stem cell transplantation under cytomegalovirus antigenemia-guided active screening

Mori T., Kikuchi T., Koh M., Koda Y., Yamazaki R., Sakurai M., Tomita Y., Ozawa Y., Kohashi S., Abe R., Saburi M., Kato J.

Bone Marrow Transplantation (Bone Marrow Transplantation)  56 ( 6 ) 1266 - 1271 2021.06

ISSN  02683369

　View Summary

Although cytomegalovirus (CMV) remains a leading cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (HSCT), the incidence of CMV retinitis is considered to be lower than the incidence of CMV infection in other organs following allogeneic HSCT. In this study, the incidence and characteristics of CMV retinitis were retrospectively evaluated in recipients of allogeneic HSCT. Ophthalmological screening was performed at the development of ocular symptoms or positive CMV infection using peripheral blood evaluated by pp65 antigenemia or polymerase chain reaction. Of the 514 patients, 13 patients developed CMV retinitis. The median onset of CMV retinitis was day 34 (range, 21–118) post transplant, and the cumulative incidence was 2.5% (95% CI, 1.6–4.2) at 6 months after transplantation. Five patients presented ocular symptoms at the onset. In the remaining eight asymptomatic patients, the diagnosis of CMV retinitis was made by the screening guided by positive CMV infection. All evaluable patients responded to antiviral treatment but three showed incomplete improvement with ocular sequela. Our results suggest that the incidence of CMV retinitis after allogeneic HSCT is not negligible and active ophthalmological screening based not only on symptoms but also positive CMV infection monitoring contributes to the early diagnosis of CMV retinitis.

• Access to Document (DOI)

Phase 1 study of plerixafor in combination with total body irradiation-based myeloablative conditioning for allogeneic hematopoietic stem cell transplantation

Mori T., Kikuchi T., Yamazaki R., Koda Y., Saburi M., Sakurai M., Shigematsu N., Okamoto S., Kato J.

International Journal of Hematology (International Journal of Hematology)  113 ( 6 ) 877 - 883 2021.06

ISSN  09255710

　View Summary

Plerixafor, a CXCR4 inhibitor, has the potential to mobilize leukemic cells, which may contribute to their chemosensitization. This phase 1 study evaluated the safety of myeloablative conditioning combined with plerixafor for allogeneic hematopoietic stem cell transplantation (HSCT). Patients with high-risk leukemia undergoing allogeneic HSCT after total body irradiation (TBI, 12 Gy)-based myeloablative conditioning were eligible; 9 patients were enrolled. The study was performed using a 3 + 3 design with an escalating total dose of plerixafor. Plerixafor was given subcutaneously 8 h before TBI and chemotherapeutic agents. Plerixafor was successfully escalated to the maximum dose (0.72 mg/kg) without dose-limiting toxicities. Underlying diseases were acute myelogenous and lymphoblastic leukemia, chronic myeloid leukemia, and myelodysplastic syndrome. As adverse events, plerixafor administration was associated with transient Grades 2–3 diarrhea (n = 7) and abdominal pain (n = 4). In 6 patients, leukemic cell mobilization into the peripheral blood by plerixafor was confirmed by a morphological or molecular method. All patients achieved neutrophil engraftment and 5 were alive in remission at a follow-up after 30–40 months. Plerixafor-combined myeloablative conditioning for allogeneic HSCT was well tolerated. Leukemic-cell mobilization into peripheral blood was observed in half of the patients. Further study is required to evaluate the efficacy and safety of this concept.

• Access to Document (DOI)

Impact of Specific Antibody Level on Human Herpesvirus 6 Reactivation after Allogeneic Stem Cell Transplantation: H. Nakayama et al

Nakayama H., Yamazaki R., Kato J., Koda Y., Sakurai M., Mori T.

Transplantation and Cellular Therapy (Transplantation and Cellular Therapy)  27 ( 2 ) 174.e1 - 174.e5 2021.02

ISSN  26666367

　View Summary

The majority of adults are seropositive for human herpesvirus 6 (HHV-6). HHV-6 reactivation can occur after allogeneic hematopoietic stem cell transplantation (HSCT) and lead to life-threatening central nervous system disorders. In this prospective study, we evaluated the relationship between HHV-6 reactivation and anti-HHV-6 IgG antibody levels in recipients of allogeneic HSCT. The HHV-6 viral load in the plasma was quantitatively measured weekly after allogeneic HSCT by real-time polymerase chain reaction. The level of anti-HHV-6 IgG antibody was measured by enzyme‐linked immunosorbent assay before and serially after transplantation. In 28 of the 56 evaluated patients (50%), HHV-6 reactivation was detected after transplantation. In a multivariate analysis, cord blood as the stem cell source was the only significant factor associated with HHV-6 reactivation (odds ratio, 8.6; 95% confidence interval, 2.3 to 32.6; P < .01). When evaluated in the recipients of cord blood transplantation (CBT), the anti-HHV-6 antibody level before transplantation was significantly lower in the patients with HHV-6 reactivation compared with those without (sample positivity index: median, 2.04 [range, 0.95 to 5.98] versus 4.15 [range, 3.93 to 5.65]; P < .05). The anti-HHV-6 antibody level was significantly decreased at 3 months post-transplantation compared with before transplantation (P < .01). Such differences were not observed in other stem cell sources. Our results demonstrate that the low anti-HHV-6 antibody level before transplantation was associated with the reactivation of HHV-6 after CBT, and that the anti-HHV-6 antibody level was significantly decreased specifically after CBT. These results suggest that HHV-6-specific humoral immunity plays a role in HHV-6 reactivation after CBT.

• Access to Document (DOI)

Detection of residual disease in chronic myeloid leukemia utilizing genomic next generation sequencing reveals persistence of differentiated Ph⁺ B cells but not bone marrow stem/progenitors

Karigane D., Kasahara H., Shiroshita K., Fujita S., Kobayashi H., Tamaki S., Yamazaki R., Yahagi K., Yatabe Y., Kondoh N., Arai T., Katagiri H., Shimizu N., Sakurai M., Kikuchi T., Kato J., Shimizu T., Hayakawa T., Yaguchi T., Matsushita M., Nakajima H., Kawakami Y., Murata M., Mori T., Sasaki T., Okamoto S., Takubo K.

Leukemia and Lymphoma (Leukemia and Lymphoma)  62 ( 3 ) 679 - 687 2021

ISSN  10428194

　View Summary

Persistence of leukemic stem cells (LSCs) results in the recurrence of chronic myeloid leukemia (CML) after the administration of tyrosine kinase inhibitors (TKIs). Thus, the detection of minimal residual disease (MRD) with LSC potential can improve prognosis. Here, we analyzed 115 CML patients and found that CD25 was preferentially expressed on the phenotypic stem and progenitor cells (SPCs), and TKI therapy decreased the number of CD25-positive cells in the SPC fraction. To detect MRD harboring BCR-ABL1 fusion DNA, we developed a highly-sensitive method using patient-specific primers and next-generation sequencing. By using this method, we identified that in patients who achieved molecular remission, almost all residual CD25-positive SPCs were BCR-ABL1-negative. Moreover, in some patients BCR-ABL1 was detectable in peripheral B cells but not in SPCs. We conclude that CD25 marks LSCs at diagnosis but does not mark MRD following TKI treatment and that analysis of peripheral B cells can allow sensitive detection of MRD.

• Access to Document (DOI)

Recurrent bacterial pneumonia due to immunoglobulin G2 subclass deficiency after allogeneic hematopoietic stem cell transplantation: Efficacy of immunoglobulin replacement

Yamazaki, Rie, Kikuchi, Taku, Kato, Jun, Sakurai, Masatoshi, Koda, Yuya, Hashida, Risa, Yamane, Yusuke, Abe, Ryohei, Hasegawa, Naoki, Okamoto, Shinichiro, Mori, Takehiko

TRANSPLANT INFECTIOUS DISEASE 20 ( 3 ) 436 - 440 2018.06

Research paper (scientific journal),  ISSN  1398-2273

• Access to Document (DOI)

Reduced-dose (two-thirds) R-CHOP chemotherapy for elderly patients with non-Hodgkin lymphoma

Kikuchi, Misato, Nakasone, Hideki, Akahoshi, Yu, Nakano, Hirofumi, Ugai, Tomotaka, Wada, Hidenori, Yamasaki, Ryoko, Sakamoto, Kana, Kawamura, Koji, Ishihara, Yuko, Sato, Miki, Ashizawa, Masahiro, Terasako-Saito, Kiriko, Kimura, Shun-ichi, Yamazaki, Rie, Kako, Shinichi, Kanda, Junya, Nishida, Junji, Sekiguchi, Naohiro, Noto, Satoshi, Kida, Michiko, Hangaishi, Akira, Usuki, Kensuke, Kanda, Yoshinobu

JOURNAL OF CHEMOTHERAPY 27 ( 2 ) 99 - 105 2015.02

Research paper (scientific journal), Joint Work,  ISSN  1120-009X

• Access to Document (DOI)

Prophylactic role of long-term ultra-low-dose acyclovir for varicella zoster virus disease after allogeneic hematopoietic stem cell transplantation

Kawamura, Koji, Wada, Hidenori, Yamasaki, Ryoko, Ishihara, Yuko, Sakamoto, Kana, Ashizawa, Masahiro, Sato, Miki, Machishima, Tomohito, Terasako, Kiriko, Kimura, Shun-ichi, Kikuchi, Misato, Nakasone, Hideki, Yamazaki, Rie, Kanda, Junya, Kako, Shinichi, Tanihara, Aki, Nishida, Junji, Kanda, Yoshinobu

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES 19   26 - 32 2014.02

Research paper (scientific journal), Joint Work,  ISSN  1201-9712

• Access to Document (DOI)

The safety and efficacy of acute graft-versus-host disease prophylaxis with a higher target blood concentration of cyclosporine around 500 ng/mL

Machishima, Tomohito, Kako, Shinichi, Wada, Hidenori, Yamasaki, Ryoko, Ishihara, Yuko, Kawamura, Koji, Sakamoto, Kana, Sato, Miki, Ashizawa, Masahiro, Terasako, Kiriko, Kimura, Shun-ichi, Kikuchi, Misato, Nakasone, Hideki, Kanda, Junya, Yamazaki, Rie, Nishida, Junji, Kanda, Yoshinobu

CLINICAL TRANSPLANTATION 27 ( 5 ) 749 - 756 2013.09

Research paper (scientific journal), Joint Work,  ISSN  0902-0063

• Access to Document (DOI)

Recurrence of monoclonal gammopathy associated with donor-derived myelodysplastic syndrome after cord blood stem cell transplantation

Yamazaki, Rie, Nakasone, Hideki, Wada, Hidenori, Sakamoto, Kana, Ashizawa, Masahiro, Sato, Miki, Terasako, Kiriko, Kikuchi, Misato, Kimura, Shun-ichi, Okuda, Shinya, Kako, Shinichi, Tanaka, Yukie, Tanihara, Aki, Oshima, Kumi, Nishida, Junji, Kanda, Yoshinobu

EXPERIMENTAL HEMATOLOGY 39 ( 12 ) 1119 - 1123 2011.12

Research paper (scientific journal), Joint Work,  ISSN  0301-472X

• Access to Document (DOI)

Association between serum high-molecular-weight adiponectin level and the severity of chronic graft-versus-host disease in allogeneic stem cell transplantation recipients

Nakasone, Hideki, Phan Nguyen Thanh Binh, Yamazaki, Rie, Tanaka, Yukie, Sakamoto, Kana, Ashizawa, Masahiro, Sato, Miki, Terasako, Kiriko, Kimura, Shun-ichi, Kikuchi, Misato, Kako, Shinichi, Okuda, Shinya, Oshima, Kumi, Tanihara, Aki, Nishida, Junji, Abe, Yasunori, Kanda, Yoshinobu

BLOOD 117 ( 12 ) 3469 - 3472 2011.03

Research paper (scientific journal), Joint Work,  ISSN  0006-4971

• Access to Document (DOI)

Single-Cell Analysis of T-Cell Receptor Repertoire of HTLV-1 Tax-Specific Cytotoxic T Cells in Allogeneic Transplant Recipients with Adult T-Cell Leukemia/Lymphoma

Tanaka, Yukie, Nakasone, Hideki, Yamazaki, Rie, Sato, Ken, Sato, Miki, Terasako, Kiriko, Kimura, Shun-ichi, Okuda, Shinya, Kako, Shinichi, Oshima, Kumi, Tanihara, Aki, Nishida, Junji, Yoshikawa, Toshiaki, Nakatsura, Tetsuya, Sugiyama, Haruo, Kanda, Yoshinobu

CANCER RESEARCH 70 ( 15 ) 6181 - 6192 2010.08

Research paper (scientific journal), Joint Work,  ISSN  0008-5472

• Access to Document (DOI)

Prediction of infectious events by high-sensitivity C-reactive protein level before undergoing chemotherapy for acute myeloid leukaemia

Sato, Miki, Kako, Shinichi, Oshima, Kumi, Sato, Ken, Terasako, Kiriko, Kimura, Shun-Ichi, Nakasone, Hideki, Okuda, Shinya, Yamazaki, Rie, Higuchi, Takakazu, Nishida, Junji, Kanda, Yoshinobu

SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES 42 ( 2 ) 97 - 101 2010

Research paper (scientific journal), Joint Work,  ISSN  0036-5548

• Access to Document (DOI)

Non-Tuberculous Mycobacterial Infection Localized in Small Intestine Developing after Allogeneic Bone Marrow Transplantation

Yamazaki, Rie, Mori, Takehiko, Nakazato, Tomonori, Aisa, Yoshinobu, Imaeda, Hiroyuki, Hisamatsu, Tadakazu, Hibi, Toshifumi, Okamoto, Shinichiro

INTERNAL MEDICINE 49 ( 12 ) 1191 - 1193 2010

Research paper (scientific journal),  ISSN  0918-2918

• Access to Document (DOI)

Successful treatment of young-onset adult T cell leukemia/lymphoma and preceding chronic refractory eczema and corneal injury by allogeneic hematopoietic stem cell transplantation

Miyamura, Fumiya, Kako, Shinichi, Yamagami, Hiroko, Sato, Ken, Sato, Miki, Terasako, Kiriko, Kimura, Shun-ichi, Nakasone, Hideki, Aoki, Satoko, Okuda, Shinya, Yamazaki, Rie, Oshima, Kumi, Yoshinaga, Kentaro, Higuchi, Takakazu, Nishida, Junji, Demitsu, Toshio, Kakehashi, Akihiro, Kanda, Yoshinobu

INTERNATIONAL JOURNAL OF HEMATOLOGY 90 ( 3 ) 397 - 401 2009.10

Research paper (scientific journal), Joint Work,  ISSN  0925-5710

• Access to Document (DOI)

Reverse seroconversion of hepatitis B virus after allogeneic hematopoietic stem cell transplantation in the absence of chronic graft-versus-host disease

Oshima, Kumi, Sato, Miki, Okuda, Shinya, Terasako, Kiriko, Nakasone, Hideki, Kako, Shinichi, Yamazaki, Rie, Tanaka, Yukie, Tanihara, Aki, Higuchi, Takakazu, Nishida, Junji, Nakamura, Ikuo, Yoshida, Yukio, Kanda, Yoshinobu

HEMATOLOGY 14 ( 2 ) 73 - 75 2009.04

Research paper (scientific journal), Joint Work,  ISSN  1024-5332

• Access to Document (DOI)